Hilma Biocare Retatrutide 10 mg

Hilma Biocare Retatrutide 10 mg — Weight loss & metabolic control

Hilma Biocare Retatrutide 10 mg is a triple‑agonist (GIP/GLP‑1/Glucagon) peptide designed to promote significant weight loss while supporting blood‑sugar regulation. It acts in a manner similar to the investigational drug (e.g., tirzepatide + glucagon activity) and is administered as a weekly subcutaneous injection.

What it does

• Boosts insulin secretion and reduces glucagon release (via GIP & GLP‑1 pathways).
• Activates glucagon receptors to increase energy expenditure.
• Suppresses appetite and prolongs satiety, leading to reduced caloric intake.
• Improves metabolic markers such as fasting glucose, HbA1c, and lipid profile.

How to use it

• Dosing schedule: Start at 2 mg once weekly, increase by 2 mg every 4 weeks (4 mg, 6 mg, then 8 mg, finally 10 mg). Higher doses (12–14 mg) may be considered if tolerated and required.
• Duration: Minimum 16 weeks to assess response; many protocols continue 24‑36 weeks or longer based on clinical goals.
• Administration: Inject subcutaneously (abdomen, thigh, or upper arm) once per week using aseptic technique. Store refrigerated (2‑8 °C) and protect from light.

Getting the best results

• Combine with a balanced, calorie‑controlled diet and regular physical activity.
• Stay well‑hydrated, especially during dose‑titration when gastrointestinal symptoms are common.
• Gradual dose escalation helps mitigate nausea, vomiting, and other digestive side effects.

Side effects to expect

Common (mild‑moderate): Nausea, vomiting, diarrhea, constipation, decreased appetite, mild abdominal discomfort, headache.

Serious (rare): Acute pancreatitis, severe abdominal pain, gallbladder disease, dehydration, allergic reactions (rash, swelling, difficulty breathing).

Important safety information

• Contra‑indicated in pregnancy, lactation, or known hypersensitivity to the peptide.
• Use caution with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
• Monitor renal function if severe vomiting occurs; hydrate aggressively.
• Review concomitant medications for potential drug‑interaction risks (e.g., insulin, sulfonylureas).

For precise dosing calculations and reconstitution guidance, we recommend using our peptide dosage & reconstitution calculator.